<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>

<!-- This file generated using Python HTMLgen module. -->
<HEAD>
  <META NAME="GENERATOR" CONTENT="HTMLgen 2.2.2">
        <TITLE>Drug Interaction Knowledge Base 1.2</TITLE>

 <LINK rel=stylesheet href="html/HTMLgen.css" type="text/css" title="html/HTMLgen.css">
</HEAD>
<BODY BGCOLOR="#FFFFFF" TEXT="#000000" LINK="#0000FF" VLINK="#EE0000">
<span style="width: 60px"></span> 
<IMG src="./images/blank.gif" height="22" width="66" alt="blank.gif"> 
<IMG src="./images/blank.gif" height="22" width="66" alt="blank.gif"> 
<IMG src="./images/blank.gif" height="22" width="66" alt="blank.gif"> 
<H3>Drug Interaction Knowledge Base 1.2</H3>
<H2>duloxetine_substrate_of_cyp2d6</H2>
<HR>

<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>

<!-- This file generated using Python HTMLgen module. -->
<HEAD>
  <META NAME="GENERATOR" CONTENT="HTMLgen 2.2.2">
        <TITLE></TITLE>

 <LINK rel=stylesheet href="html/HTMLgen.css" type="text/css" title="html/HTMLgen.css">
</HEAD>
<BODY BGCOLOR="#FFFFFF" TEXT="#000000" LINK="#0000FF" VLINK="#EE0000">
<b>You can go to DIKB assertion index here:</b>  
<A HREF="/dikb-evidence/index.html">DIKB assertion index</A>
<br><b>You can go to DIKB the home page here:</b>  
<A HREF="/dikb-evidence/front-page.html">DIKB Front Page</A>

<P>

<a name="
duloxetine_substrate_of_cyp2d6
"></a>
<b>Assertion:
duloxetine substrate_of cyp2d6
</b>
<BR>
<A NAME="Evidence"></A>
<P><TABLE border=2 cellpadding=4 cellspacing=1 width="100%">
<CAPTION align=top><STRONG>Evidence</STRONG></CAPTION>
<TR><TD Align=left ><STRONG>Evidence For (item 0)</STRONG></TD>
<TD Align=left ><STRONG>Evidence Type: </STRONG>Non_traceable_Drug_Label_Statement</TD>
<TD Align=left ><STRONG>Pointer: </STRONG>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-</TD>
<TD Align=left ><STRONG>Reviewer: </STRONG>boycer</TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>Quote: </STRONG>7.2 Inhibitors of CYP2D6<br><br>Concomitant use of duloxetine (40 mg once daily) with paroxetine (20 mg once daily) increased the concentration of duloxetine AUC by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine. Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine) [see Warnings and Precautions (5.10)].</TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>Assumptions: </STRONG>paroxetine_in_viVo_selective_inhibitor_of_enzyme_cyp2d6</TD>
</TR>
<TR><TD Align=left ><STRONG>Evidence For (item 1)</STRONG></TD>
<TD Align=left ><STRONG>Evidence Type: </STRONG>EV_PK_DDI_NR</TD>
<TD Align=left ><STRONG>Pointer: </STRONG>http://www.ncbi.nlm.nih.gov/pubmed/12621382</TD>
<TD Align=left ><STRONG>Reviewer: </STRONG>boycer</TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>Quote: </STRONG><br><br>route of administration: oral<br><br>study duration: &quot;In study 2, there were 2 study periods separated by a least 4 days. In period 1, subjects received 40 mg duloxetine every day for 5 days. Blood samples for the measurement of duloxetine plasma concentrations were taken immediately before duloxetine dosing on days 3 4, and 5 and at 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours after dosing on day 5. In period 2, subjects received 20 mg paroxetine every day for 20 days Beginning on day 12 of this period, subjects again received duloxetine 40 mg every day for 5 days and samples were taken as in period 1, except that additional samples were taken 96 and 120 hours after the &amp;#64257;nal duloxetine dose. On the &amp;#64257;nal day of duloxetine dosing in each period, subjects fasted from midnigh until 4 hours after dosing. All doses of study drugs were supervised by study site personnel. &quot;<br><br>population: 12 male; 11 of 12 were of Chinese or Malay decent NOTE: only 10 completed the study<br><br>tested for known CYP450 polymorphisms? yes but exact genotype not mentioned only that all were genotypically CYP2D6 extensive metabolizers.<br><br>ages: 21 - 27<br><br>description:<br>&quot;Paroxetine increased the maximum plasma concentration of duloxetine and the area under the concentration-time curve at steady state 1.6-fold.&quot;<br><br></TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>Assumptions: </STRONG>paroxetine_in_viVo_selective_inhibitor_of_enzyme_cyp2d6</TD>
</TR>
<TR><TD Align=left ><STRONG>No evidence against!</STRONG></TD>
</TR>
</TABLE><P>

<BR>

</BODY> </HTML>

<b>You can go to DIKB assertion index here:</b>  
<A HREF="/dikb-evidence/index.html">DIKB assertion index</A>
<br><b>You can go to DIKB the home page here:</b>  
<A HREF="/dikb-evidence/front-page.html">DIKB Front Page</A>

<P>

<BR><BR><a rel="license" href="http://creativecommons.org/licenses/by-nc-sa/3.0/"><img alt="Creative Commons License" style="border-width:0" src="http://i.creativecommons.org/l/by-nc-sa/3.0/88x31.png" /></a><br /><span xmlns:dct="http://purl.org/dc/terms/" href="http://purl.org/dc/dcmitype/Dataset" property="dct:title" rel="dct:type">Drug Interaction Knowledge Base (DIKB)</span> by <a xmlns:cc="http://creativecommons.org/ns#" href="http://www.dbmi.pitt.edu/person/richard-boyce-phd" property="cc:attributionName" rel="cc:attributionURL">Richard D. Boyce</a> is licensed under a <a rel="license" href="http://creativecommons.org/licenses/by-nc-sa/3.0/">Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License</a>.

<P><HR>
<span style="width: 60px"></span> 
<IMG src="./images/blank.gif" height="22" width="66" alt="blank.gif"> 
<IMG src="./images/blank.gif" height="22" width="66" alt="blank.gif"> 
<IMG src="./images/blank.gif" height="22" width="66" alt="blank.gif"> 
<BR><IMG src="./images/logo.jpg" alt="logo.jpg" align="bottom">
<FONT SIZE="-1"><P>Copyright &#169 (c) 2005-2012 Richard David Boyce<BR>All Rights Reserved<BR>

Comments to author: <A HREF="mailto:&#114;d&#98;2&#48; &#97;t&#32;p&#105;t&#116; &#60;d&#111;t&#62; &#101;d&#117;">rdb20 at pitt <dot> edu</A><br>
Generated: Thu Jul 30, 2015 <BR><hr>
</FONT>
</BODY> </HTML>
